Stockscreener 앱 받기
4.04
9.19%
0.34
시장 영업 전:
4.09
0.05
+1.24%
전일 마감가:
$3.70
열려 있는:
$3.79
하루 거래량:
4.22M
Relative Volume:
1.07
시가총액:
$729.26M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-1.8618
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
+16.43%
1개월 성능:
+8.02%
6개월 성능:
+6.32%
1년 성능:
+23.17%
1일 변동 폭
$3.75
$4.17
1주일 범위
$3.3314
$4.17
52주 변동 폭
$1.11
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.04 | 667.89M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine (NYSE:PRME) Trading 7.5% HigherWhat's Next? - MarketBeat
How Prime Medicine Inc. stock reacts to oil pricesBullish Engulfing Patterns & High Profit Trading Alerts - ulpravda.ru
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Prime Medicine, Inc. (PRME) announces NEJM publication of PM359 data - MSN
Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - Benzinga
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond - Seeking Alpha
Prime Medicine (NYSE:PRME) Trading Down 3.3%Here's What Happened - MarketBeat
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases - Insider Monkey
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data - Insider Monkey
10 Best Biotech Penny Stocks to Buy According to Analysts - Insider Monkey
Lifesci Capital Predicts Prime Medicine FY2025 Earnings - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Down 3.8%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 4.2%Should You Sell? - MarketBeat
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Prime Medicine (PRME) with Outperform Recommendation - Nasdaq
Lifesci Capital Begins Coverage on Prime Medicine (NYSE:PRME) - MarketBeat
LifeSci Capital Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $6 - 富途牛牛
Prime Medicine: Buy Rating on Prime Editing Platform Targeting High-Value Liver and Lung Genetic Diseases, Led by PM577 in Wilson’s Disease - TipRanks
Prime Medicine initiated with an Outperform at LifeSci Capital - TipRanks
LifeSci Initiates Prime Medicine at Outperform With $6 Price Target - marketscreener.com
Prime Medicine Earnings Notes - Trefis
Prime Medicine, Inc.(NasdaqGM: PRME) added to S&P Biotechnology Select Industry Index - marketscreener.com
Prime Medicine announces NEJM publication of PM359 data - MSN
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: How Prime Medicine Inc. stock reacts to oil pricesWatch List & Safe Entry Trade Reports - Улправда
Risks Report: Why Prime Medicine Inc. stock remains resilient2025 Market Trends & Real-Time Buy Signal Notifications - Улправда
What technical charts say about Prime Medicine Inc. stockEarnings Overview Report & AI Powered Market Entry Strategies - Улправда
Why Prime Medicine Inc. stock remains resilientTrade Exit Summary & Weekly High Return Stock Forecasts - Улправда
Can Prime Medicine Inc. stock hit record highs againJuly 2025 News Drivers & Weekly High Conviction Ideas - Улправда
Can Prime Medicine Inc. stock withstand economic slowdownTrade Signal Summary & Weekly Top Gainers Alerts - Улправда
Is Prime Medicine Inc. stock in correction or buying zone2025 Stock Rankings & Consistent Growth Equity Picks - DonanımHaber
Profit Recap: How Prime Medicine Inc. stock reacts to oil pricesRate Hike & Accurate Intraday Trading Signals - Улправда
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance - StocksToTrade
Prime Medicine (NYSE:PRME) Shares Gap UpShould You Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Shares Gap UpStill a Buy? - MarketBeat
Prime Medicine Announces The New England Journal of - GlobeNewswire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease - Sahm
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Prime Medicine (NYSE:PRME) Stock Price Up 10.2%Still a Buy? - MarketBeat
Prime Medicine (NASDAQ:PRME) Trading Up 11.1%Here's What Happened - MarketBeat
Will Prime Medicine Inc. stock deliver better than expected guidance2025 Sector Review & Safe Capital Preservation Plans - Newser
Prime Medicine (PRME) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Prime Medicine (NASDAQ:PRME) Stock Price Down 7.3%Here's What Happened - MarketBeat
Prime Medicine (NYSE:PRME) Stock Price Down 7.2%Here's Why - MarketBeat
PRME: Prime editing advances with focused clinical programs and data expected in 2027 - TradingView — Track All Markets
Prime Medicine (PRME) Competitors and Alternatives 2025 - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
28.63%
자본화:
|
볼륨(24시간):